Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07360457 for Osteoarthritis is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Beni-Suef UniversityGLP1 Analogues and the Risk of Osteoarthritis 390
Clinical Trial NCT07360457 is an observational study for Osteoarthritis and is currently not yet recruiting. Enrollment is planned to begin on February 1, 2026 and continue until the study accrues 390 participants. Led by Beni-Suef University, this study is expected to complete by March 1, 2027. The latest data from ClinicalTrials.gov was last updated on January 22, 2026.
Brief Summary
Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.
Detailed Description
Osteoarthritis (OA) is a multifactorial joint disease related to multiple inflammatory pathways which are triggered by mechanical and cellular stress, leading to increased production of pro-inflammatory mediators, reactive oxygen species, advanced glycation end products (AGEs). These mediators promote the release of proteolytic enzymes, which degrade the cartilage matrix. A recent study emphasized on the relation bet...Show More
Official Title
Association of GLP1 Analogues and SGLT2 Inhibitors With the Risk of Osteoarthritis in Type 2 Diabetic Patients
Conditions
OsteoarthritisOther Study IDs
- GLP1
NCT ID Number
Start Date (Actual)
2026-02-01
Last Update Posted
2026-01-22
Completion Date (Estimated)
2027-03-01
Enrollment (Estimated)
390
Study Type
Observational
Status
Not yet recruiting
Keywords
GLP-1
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
SGLT2 Group T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care | SGLT2 inhibitor sodium glucose transporter-2 inhibitors |
GLP1 Group T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care | GLP-1 analog glucagon like peptide analogues |
Control group T2DM patients receiving only standard of care | Antidiabetic Standard of care |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
WOMAC score | A validated, self-administered questionnaire used to assess pain, stiffness, and physical function | at Day 1 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
VAS pain score | numerical measure to assess pain | at Day 1 |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
50 Years
Eligible Sexes
All
- Adults aged above 50 years old with a previous diagnosis of T2DM according to ADA 2025, who have been on either SGLT2 inhibitors or GLP-1 analogs for at least one year.
- individuals with Type 1 Diabetes Mellitus
- non-diabetic individuals
- those taking prandial insulin
- patients with arthritis without osteoarthritis,
- those taking other medications contraindicated with study medications,
- pregnant or breastfeeding females
- those allergic to active ingredients,
- those using corticosteroids, Autoimmune disease patients or patients receiving immunotherapies, monoclonal antibody targeting TNF-α or IL-6.
Beni-Suef University55 active studies to exploreStudy Responsible Party
Asmaa Abdelfattah Elsayed, Principal Investigator, Lecturer of clinical pharmacy, Beni-Suef University
Study Central Contact
Contact: Asmaa A Elsayed, 01095727201, [email protected]
No location data.